Retrovirus Packaging Cell Using Temperature-Sensitive RdRp
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of lentiviral vectors is hindered by the lack of stable producer cells and low viral titers due to challenges in expressing and folding gagpol proteins and the toxicity associated with lentiviral proteins, as well as limitations in nuclear export and cytoplasmic accumulation of transfer vector transgenes.
Innovation Solution
The use of RNA-dependent RNA polymerase (RdRp) to amplify retroviral transfer vector transgenes in the cytoplasm and control the expression of toxic retroviral proteins through a temperature-sensitive RdRp system, allowing for controllable induction of protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high numbers of transfer vector transgenes are needed to generate appropriate viral titres, then viral titre is improved, but nuclear export limitation causes transgene accumulation in cytoplasm to be insufficient
Solution Approach 1:
The patent introduces RdRp promoter elements into the transfer vector transgene structure before transfection into producer cells. This preliminary genetic modification enables the transgene to be transcribed by RdRp upon infection, allowing cytoplasmic amplification of transgene RNA before viral assembly occurs. This preliminary preparation of the genetic structure resolves the contradiction by enabling sufficient transgene accumulation in the cytoplasm without requiring increased nuclear export capacity.
Solution Approach 2:
The patent introduces RdRp (RNA-dependent RNA polymerase) as an intermediary enzyme that bridges the gap between nuclear transgene transcription and cytoplasmic viral assembly. RdRp acts as a mediator that amplifies transgene RNA in the cytoplasm, converting limited nuclear-exported transgene RNA into abundant cytoplasmic RNA copies sufficient for high viral titre production without requiring improved nuclear export mechanisms.
2Quantity of substance
If high levels of lentiviral proteins such as gagpol and envelope proteins are needed to produce required lentiviral titres, then viral titre is improved, but basal toxicity associated with protease activity and syncytial formation increases
Solution Approach 1:
The patent employs temperature-sensitive RdRp that can be activated or deactivated by changing culture temperature. At permissive temperatures (e.g., 33°C), RdRp is active and enables transgene amplification and viral production. At non-permissive temperatures (e.g., 37°C), RdRp activity is reduced, minimizing basal toxicity from continuous lentiviral protein expression. This dynamic temperature control resolves the contradiction by allowing high protein levels only when needed for viral production while minimizing continuous toxic effects.
Solution Approach 2:
The patent implements periodic induction of lentiviral protein expression through temperature shifts. Producer cells are maintained at a temperature that keeps RdRp inactive (minimizing basal toxicity), then periodically shifted to activate RdRp for transgene amplification and viral production. This periodic activation pattern allows accumulation of viral proteins needed for high titre while limiting continuous exposure to toxic protein levels, resolving the contradiction between protein quantity and toxicity.
3Productivity
If stable packaging cell lines are developed to enable large scale production, then productivity is improved, but the complexity of achieving stable integration and maintenance of multiple transgenes increases
Solution Approach 1:
The patent segments the lentiviral production system into three separate plasmid components: (1) transfer vector containing the transgene and RdRp promoter elements, (2) packaging plasmid containing gagpol and other essential viral proteins, and (3) envelope plasmid containing the envelope gene. This segmentation allows each component to be independently optimized and stably integrated into producer cells, reducing the complexity of maintaining multiple transgenes simultaneously while enabling large-scale production through controlled co-expression.
Solution Approach 2:
The patent uses RdRp as an intermediary mechanism that simplifies stable cell line construction. By introducing RdRp promoter elements into the transfer vector, the system enables cytoplasmic amplification of transgene RNA without requiring complex nuclear export mechanisms or multiple stable integrations. The RdRp intermediary allows transient expression systems to achieve stability comparable to integrated systems, reducing the complexity of stable cell line construction while maintaining high productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables high-titer lentiviral vector production by overcoming limitations in nuclear export and protein expression, achieving efficient viral vector production while minimizing cellular toxicity.
Implementation Method 1
levels of retroviral transfer vector transgenes may be amplified during retroviral vector production by using an RNA-dependent RNA polymerase (RdRp) to amplify the transgenes in the cytoplasm of a producer cell
Implementation Method 2
The use of packaging cells or producer cells which (i) comprise nucleic acid sequences that are transcribed into mRNA which encodes toxic retroviral proteins, such as gagpol and env proteins, under the control of a RdRp subgenomic promoter and (ii) expressing a temperature sensitive RdRp; enables the expression of the toxic retroviral proteins to be induced in a controllable manner
Data Source
AI summary
The present invention relates to a retrovirus packaging cell which expresses a temperature sensitive RNA-dependent-RNA polymerase (RdRp).